Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Marc Grodman, Charles Todd, Steve Lombardi

Premium

Marc Grodman, CEO of Bio-Reference Laboratories, will chair the board of directors of InCellDx, BRL announced this week. Additionally, Charles Todd of BRL will also be appointed to the six-person InCellDx board. These appointments come as BRL has purchased between 20 percent and 25 percent of InCellDx's preferred stock for $4 million in cash and $2 million by promissory note.


Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.